Special Issue

Targeted Treatment of Lymphoma, Leukaemia and Myeloma

Message from the Guest Editor

Our understanding of tumor biology has led to the development of several therapies targeting specific genes and proteins involved in the growth and survival of cancer cells. This transformation is most apparent in lymphoma and leukaemia, where therapies targeting Bruton tyrosine kinase, phosphatidylinositol 3-kinase inhibitors, and B-cell lymphoma 2 are already in clinics. The role of the immune system in tumor eradication has led to the development of second-generation CD20 antibodies, chimeric antigen receptor T-cells, and agents acting on key immune checkpoints. Agents acting on DNA methylation or histone protein modification are also active in certain lymphoid malignancies. Several of these agents are superior to conventional chemoimmunotherapy although they are not without risks. This Special Issue will provide a comprehensive overview of current clinical research in lymphoma and leukaemia with special reference to targeted therapies, including the utility of specific drugs/combinations and strategies in various clinical and biological subgroups.

Guest Editor

Prof. Stephen Opat

Department of Haematology, School of Clinical Sciences at Monash Health, Monash University, Wellington Rd, Clayton, VIC 3800, Australia

Deadline for manuscript submissions

closed (20 July 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/55101

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

